KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Weighted Average and Diluted) (2019 - 2025)

Novavax has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at $0.05 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.05 for Q4 2025, up 109.62% from a year ago — trailing twelve months through Dec 2025 was $2.35 (up 275.37% YoY), and the annual figure for FY2025 was $2.58, up 309.76%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.05 at Novavax, up from -$1.25 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for NVAX hit a ceiling of $2.93 in Q1 2025 and a floor of -$11.31 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.25 (2025), compared with a mean of -$1.82.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1483.33% in 2021 and later surged 379.05% in 2025.
  • Novavax's EPS (Weighted Average and Diluted) stood at -$11.31 in 2021, then soared by 79.75% to -$2.29 in 2022, then skyrocketed by 35.81% to -$1.47 in 2023, then surged by 64.63% to -$0.52 in 2024, then surged by 109.62% to $0.05 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.05 (Q4 2025), -$1.25 (Q3 2025), and $0.62 (Q2 2025) per Business Quant data.